Trial Profile
Phase 4 study of dual five alpha reductase inhibition [dutasteride] combined with alpha blockade [alpha adrenergic receptor antagonists] in men with refractory urinary retention secondary to BPH [benign prostatic hyperplasia]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary) ; Alpha adrenergic receptor antagonists
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- 07 Jun 2008 New trial record.